Details of the Drug

General Information of Drug (ID: DMWQ16I)

• Drug Name: Primaquine
• Synonyms: Kanaprim; Primachin; Primachina; Primachinum; Primaquin; Primaquina; Primaquinum; Primachina [DCIT]; SN 13272; WR 2975; Dl-Primaquine; Kanaprim (TN); Neo-Quipenyl; Primaquina [INN-Spanish]; Primaquine (INN); Primaquine Bis-Phosphoric Acid; Primaquine [INN:BAN]; Primaquinum [INN-Latin]; SN 13,272; TG1-296; TG1-297; Ethylbutylamino)-6-methoxyquinoline; S. N. 13272; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-(6CI,8CI); (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (+)-Primaquine; (+/-)-Primaquine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-Primaquine; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-(9CI); 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; 6-Methoxy-8-[4-amino-1-methylbutylamino]quinoline; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; 8-(4-Amino-1-m; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline

Indication

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Approved	[1]

• Therapeutic Class: Antimalarials
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 259.35
  Topological Polar Surface Area (xlogp); 2.2
  Rotatable Bond Count (rotbonds); 6
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
  Bioavailability: 96% of drug becomes completely available to its intended biological destination(s) [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 5.8 mL/min/kg [4]
  Elimination: 1% of drug is excreted from urine in the unchanged form [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3.7 - 7.4 hours [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.8918 micromolar/kg/day [5]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 4 L/kg [4]
• Chemical Identifiers:
  Formula: C15H21N3O
  IUPAC Name: 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
  Canonical SMILES: CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2
  InChI: InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3
  InChIKey: INDBQLZJXZLFIT-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 4908
  ChEBI ID: CHEBI:8405
  CAS Number: 90-34-6
  DrugBank ID: DB01087
  TTD ID: D0T1LK
  INTEDE ID: DR1339
  ACDINA ID: D00554

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasmodium Deoxyribonucleic acid (Malaria DNA)	TT698WO	NOUNIPROTAC	Not Available	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[7]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[8]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Primaquine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Primaquine and Lumefantrine.	Malaria [1F40-1F45]	[27]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Primaquine and Halofantrine.	Malaria [1F40-1F45]	[28]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Primaquine and Hydroxychloroquine.	Malaria [1F40-1F45]	[29]

Coadministration of a Drug Treating the Disease Different from Primaquine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Primaquine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[30]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Midostaurin.	Acute myeloid leukaemia [2A60]	[31]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Idarubicin.	Acute myeloid leukaemia [2A60]	[31]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Arn-509.	Acute myeloid leukaemia [2A60]	[32]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[33]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Oliceridine.	Acute pain [MG31]	[31]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Primaquine and Ivabradine.	Angina pectoris [BA40]	[32]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Primaquine and Bepridil.	Angina pectoris [BA40]	[31]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Primaquine and Dronedarone.	Angina pectoris [BA40]	[31]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Primaquine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[34]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Cilostazol.	Arterial occlusive disease [BD40]	[31]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Posaconazole.	Aspergillosis [1F20]	[31]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Primaquine and Levalbuterol.	Asthma [CA23]	[35]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Primaquine and Pirbuterol.	Asthma [CA23]	[36]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[32]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[31]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[37]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[31]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Primaquine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[37]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[37]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[37]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Retigabine.	Behcet disease [4A62]	[31]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Eribulin.	Breast cancer [2C60-2C6Y]	[31]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Lapatinib.	Breast cancer [2C60-2C6Y]	[31]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Bosutinib.	Breast cancer [2C60-2C6Y]	[32]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[38]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Primaquine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[36]
Vilanterol	DMF5EK1	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Primaquine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[36]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[36]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Halothane.	Corneal disease [9A76-9A78]	[31]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Sevoflurane.	Corneal disease [9A76-9A78]	[31]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Probucol.	Coronary atherosclerosis [BA80]	[31]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Primaquine and Pasireotide.	Cushing syndrome [5A70]	[31]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Osilodrostat.	Cushing syndrome [5A70]	[32]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Sertraline.	Depression [6A70-6A7Z]	[31]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Primaquine and Escitalopram.	Depression [6A70-6A7Z]	[31]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Clomipramine.	Depression [6A70-6A7Z]	[31]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Doxepin.	Depression [6A70-6A7Z]	[31]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[31]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Deutetrabenazine.	Dystonic disorder [8A02]	[39]
Ingrezza	DMVPLNC	Moderate	Additive CNS depression effects by the combination of Primaquine and Ingrezza.	Dystonic disorder [8A02]	[40]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Solifenacin.	Functional bladder disorder [GC50]	[31]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[31]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[41]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Primaquine and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[42]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Primaquine caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[32]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Primaquine caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[43]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Primaquine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[32]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Primaquine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[31]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Primaquine and Crizotinib.	Lung cancer [2C25]	[44]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Primaquine and Ceritinib.	Lung cancer [2C25]	[31]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Primaquine and Osimertinib.	Lung cancer [2C25]	[45]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Primaquine and Selpercatinib.	Lung cancer [2C25]	[32]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[32]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Primaquine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[46]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Primaquine and Vemurafenib.	Melanoma [2C30]	[31]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and LGX818.	Melanoma [2C30]	[47]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Primaquine and Panobinostat.	Multiple myeloma [2A83]	[48]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Primaquine and Siponimod.	Multiple sclerosis [8A40]	[27]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Primaquine and Fingolimod.	Multiple sclerosis [8A40]	[31]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Primaquine and Ocrelizumab.	Multiple sclerosis [8A40]	[49]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Primaquine and Ozanimod.	Multiple sclerosis [8A40]	[50]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Romidepsin.	Mycosis fungoides [2B01]	[31]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Primaquine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[31]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[51]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Primaquine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[32]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Lofexidine.	Opioid use disorder [6C43]	[31]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Rucaparib.	Ovarian cancer [2C73]	[31]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Triclabendazole.	Parasitic worm infestation [1F90]	[31]
Rasagiline	DM3WKQ4	Moderate	Decreased metabolism of Primaquine caused by Rasagiline mediated inhibition of CYP450 enzyme.	Parkinsonism [8A00]	[27]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Pimavanserin.	Parkinsonism [8A00]	[52]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Primaquine and Lefamulin.	Pneumonia [CA40]	[53]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Degarelix.	Prostate cancer [2C82]	[32]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and ABIRATERONE.	Prostate cancer [2C82]	[32]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Relugolix.	Prostate cancer [2C82]	[32]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Bicalutamide.	Prostate cancer [2C82]	[32]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[31]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Primaquine and Golimumab.	Rheumatoid arthritis [FA20]	[54]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Quetiapine.	Schizophrenia [6A20]	[31]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Aripiprazole.	Schizophrenia [6A20]	[27]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Primaquine and Iloperidone.	Schizophrenia [6A20]	[31]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Paliperidone.	Schizophrenia [6A20]	[31]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Primaquine and Amisulpride.	Schizophrenia [6A20]	[55]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Asenapine.	Schizophrenia [6A20]	[31]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Primaquine and Pimozide.	Schizophrenia [6A20]	[32]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Primaquine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[31]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Primaquine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[31]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[32]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Pitolisant.	Somnolence [MG42]	[31]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[31]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Lenvatinib.	Thyroid cancer [2D10]	[31]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Primaquine and Cabozantinib.	Thyroid cancer [2D10]	[32]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Primaquine and Papaverine.	Tonus and reflex abnormality [MB47]	[56]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[57]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[31]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Primaquine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[31]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Primaquine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[31]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Primaquine and Valganciclovir.	Virus infection [1A24-1D9Z]	[27]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd	E00585	56841934	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Water	E00035	962	Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Primaquine 26.3 mg tablet	26.3 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 008316.
• [2] BDDCS applied to over 900 drugs
• [3] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays. Toxicology. 2007 Sep 24;239(1-2):96-107.
• [7] Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol. 1992 Aug 4;44(3):587-90.
• [8] Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
• [9] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [10] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [11] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [12] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [13] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [14] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [15] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [16] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [17] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [18] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [19] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [20] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [21] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [22] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [23] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [24] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [25] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [26] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [27] Cerner Multum, Inc. "Australian Product Information.".
• [28] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [29] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [30] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [31] Canadian Pharmacists Association.
• [32] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [33] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [34] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [35] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [36] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [37] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [38] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [39] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [40] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [41] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [42] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [43] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [44] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [45] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [46] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [47] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [48] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [49] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [50] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [51] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [52] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [53] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [54] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [55] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [56] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [57] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]